Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Updates from CheckMate 459

Bruno Sangro • 30 Jun 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Liver Cancer Antibodies Checkpoint Inhibitors Nivolumab Sorafenib
CheckMate 459

Bruno Sangro, MD, PhD, of Clinica Universidad de Navarra, Navarra, Spain, discusses long-term efficacy results from the Phase III CheckMate 459 study (NCT02576509), comparing nivolumab and sorafenib as first line treatment in patients with advanced hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Bruno Sangro

3:38
EMERALD-1 trial in HCC
Bruno Sangro • 3 Jul 2020
7:47
Combination tremelimumab and durvalumab in HCC
Bruno Sangro • 30 Jun 2020
2:25
Impact of COVID-19 on HCC management
Bruno Sangro • 1 Jul 2020

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals